Table 2.
Comparative analysis of average survival time after surgery and risk for recurrence of disease in CC patients with GPR55(−) and GPR55(+) and those with GPR55(−−) and GPR55(++) lymph nodes.
| Patient Group | Category | Number of Patients in Each Group Stratified by TNM Stage | Total | 5-Year Follow-Up after Surgery | 12-Year Follow-Up after Surgery | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease-Free Survival a | Risk for Recurrence b | Disease-Free Survival a | Risk for Recurrence b | |||||||||||||
| Stage I |
Stage II |
Stage III |
Stage IV |
Average (Months) |
Difference (Months) |
p-Value | Hazard Ratio (95% CI) |
p-Value | Average (Months) |
Difference (Months) |
p-Value | Hazard Ratio (95% CI) |
p-Value | |||
| GPR55 mRNA level | ||||||||||||||||
| All CC patients | GPR55(−) c | 7 | 10 | 12 | 4 | 33 | 46 | 7 | 0.12 | 0.6 (0.3–1.2) |
0.12 | 93 | 14 | 0.04 | 0.5 (0.3–1.0) |
0.05 |
| GPR55(+) | 16 | 42 | 25 | 5 | 88 | 53 | 107 | |||||||||
| CXCL16 e | GPR55(−) | 2 | 3 | 6 | 4 | 15 | 36 | 16 | 0.01 | 0.3 (0.1–0.8) |
0.02 | 60 | 40 | 0.04 | 0.4 (0.2–1.0) |
0.04 |
| GPR55(+) | 8 | 12 | 10 | 3 | 33 | 52 | 100 | |||||||||
| CXCL17 f | GPR55(−) | 2 | 2 | 7 | 2 | 13 | 40 | 17 | 0.05 | 0.3 (0.1–1.1) |
0.07 | 64 | 44 | 0.05 | 0.3 (0.1–1.1) |
0.07 |
| GPR55(+) | 3 | 5 | 6 | 2 | 16 | 57 | 108 | |||||||||
| CEA g | GPR55(−) | 4 | 5 | 3 | 0 | 12 | 51 | 4 | 0.56 | 0.7 (0.2–2.6) |
0.56 | 86 | 26 | 0.05 | 0.3 (0.1–1.1) |
0.06 |
| GPR55(+) | 6 | 17 | 10 | 0 | 33 | 55 | 112 | |||||||||
| GPR55 mRNA/CEA mRNA ratio | ||||||||||||||||
| All CC patients | GPR55(−−) d | 1 | 2 | 9 | 7 | 19 | 40 | 14 | 0.0003 | 0.3 (0.1–0.6) |
0.001 | 80 | 33 | 0.003 | 0.4 (0.2–0.7) |
0.004 |
| GPR55(++) | 22 | 50 | 28 | 2 | 102 | 54 | 113 | |||||||||
| CXCL16 e | GPR55(−−) | 1 | 0 | 8 | 7 | 16 | 38 | 13 | 0.02 | 0.4 (0.1–0.9) |
0.02 | 60 | 40 | 0.04 | 0.4 (0.2–1.0) |
0.04 |
| GPR55(++) | 9 | 15 | 8 | 0 | 32 | 51 | 100 | |||||||||
| CXCL17 h | GPR55(−−) | 0 | 2 | 1 | 3 | 6 | 35 | 19 | 0.001 | 0.2 (0.1–0.6) |
0.004 | 73 | 40 | 0.04 | 0.3 (0.1–1.0) |
0.05 |
| GPR55(++) | 18 | 43 | 22 | 2 | 85 | 54 | 113 | |||||||||
| CEA i | GPR55(−−) | 1 | 2 | 9 | 7 | 19 | 40 | 13 | 0.002 | 0.3 (0.1–0.7) |
0.004 | 80 | 26 | 0.005 | 0.3 (0.1–0.8) |
0.008 |
| GPR55(++) | 12 | 28 | 15 | 2 | 57 | 53 | 106 | |||||||||
a Mean survival time after surgery calculated by cumulative survival analysis according to the Kaplan–Meier model; b hazard ratio with 95% confidence interval (CI) calculated according to univariate Cox regression analysis; c CC patients divided into two groups, GPR55(−) and GPR55(+), using a cutoff of 0.1365 mRNA copies/18S rRNA unit; d CC patients divided into two groups, GPR55(−−) and GPR55(++), using a cutoff GPR55 mRNA/CEA mRNA ratio of 0.1481; e CC patient group with CXCL16 mRNA levels above 7.2 mRNA copies/18S rRNA unit; f CC patient group with CXCL17 mRNA levels above 0.0014 mRNA copies/18S rRNA unit; g CC patient group with CEA mRNA levels below 0.013 mRNA copies/18S rRNA unit; h CC patient group with CXCL17 levels below 0.0014 mRNA copies/18S rRNA unit.; i CC patient group with CEA mRNA levels above 0.013 mRNA copies/18S rRNA unit.